Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 17

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Non-small cell lung cancer+2

Recruiting

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cough

Recruiting

Study on the Effectiveness of Amoxicillin and Clavulanic Acid in Treating Chronic Wet Cough in Young Children

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · Healthy volunteers
  • Substances:Amoxicillin
  • Sponsor:Helse Stavanger HF

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Eosinophilic granulomatosis with polyangiitis

Recruiting

Study on the Effects of Mepolizumab on Nasal Health and Immune Response in Patients with Eosinophilic Granulomatosis with Polyangiitis (eGPA)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mepolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Chronic rhinosinusitis with nasal polyps

Recruiting

Study on How Mepolizumab Affects Patients with Chronic Rhinosinusitis with Nasal Polyps

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mepolizumab
  • Sponsor:Amsterdam UMC Stichting

Laryngitis

Recruiting

Study on the Effectiveness of Prednisolone for Treating Acute Laryngitis in Vocal Professionals

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Prednisolone
  • Sponsor:HUS-Yhtymae

Respiratory syncytial virus infection

Recruiting

Study on the Safety and Immune Response of rBCG-N-RSV Vaccine Compared to BCG Vaccine in Adults Over 60 with Respiratory Syncytial Virus (RSV) Concerns

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Biothervax SpA

Influenza

Recruiting

Study on the Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Preventing Flu in Adults Aged 65-79 in Galicia, Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Substances:A/CAMBODIA/E0826360/2020 (H3N2)-LIKE STRAIN (A/CAMBODIA/E0826360/2020 IVR-224)
  • Sponsor:Complexo Hospitalario Universitario De Santiago

COVID-19

Recruiting

Study comparing intranasal COVID-19 vaccine (LVT-001) with mRNA vaccine (bretovameran) as booster doses in healthy adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:LVT-001
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Follicular lymphoma+7

Recruiting

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Interstitial lung disease

Recruiting

Study of Rituximab versus Placebo to Improve Lung Function in Patients with Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer metastatic

Recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.